Co-isolation of genetically distinct Burkholderia pseudomallei strains from a single patient in North Queensland Authors: Pauline M. L. Coulon, Piklu Roy Chowdhury, Ian Gassiep, Kay Ramsay, Aven Lee, Edita Ritmejeryte, Miranda E. Pitt, Joyce To, Sarah Reed, Patrick N. A. Harris, Garry S. A. Myers, William C. Nierman, William C. Nierman, William C. Nierman Published: 2025 ABSTRACT While investigating colony morphology variation within clinical isolates of Burkholderia pseudomallei (Bp) isolated from a single clinical infection, we identified two distinct strains (based on their multi-locus sequence type) from Bp TSV292. Reports of simultaneous co-infection are un-common, with only two studies in Thailand documenting such cases: (1) 2 out of 133 cases, and (2) 13 out of 59 patients infected with two to three polyclonal Bp strains exhibiting different genotypes. Here, we present the first comprehensive multi-omics characterization of co-infecting Bpstrains isolated from a single infection at a hospital in Townsville, Australia, in 2018. This finding impacts the design of future diagnosis and treatment of Bp. Introduction Burkholderia pseudomallei (Bp) is an opportunistic pathogen and the causative agent of melioidosis, a severe and often fatal disease in humans and animals [1,2]. Once considered endemic mainly to tropical and subtropical regions of Asia, Africa, Central and South America, and northern Australia [1], Bp is now recognized as established in the United States [3]. Diagnosis of melioidosis is challenging, as clinical presentations vary across geographical regions and laboratory misidentification can occur, especially when culture-dependent methods rely heavily on characterization of colony morphology on blood agar [4]. While Bp acquisition and infection will not cause melioidosis in healthy populations, people living with underlying conditions, such as diabetes, chronic kidney or lung disease, alcoholism, or compromised immune systems are at greater risk. In these populations, melioidosis often manifests as skin abscesses or severe pneumonia, which can progress to fatal sepsis with mortality rates reaching up to 52% [5]. With climate change intensifying extreme weather events such as heavy rainfall and flooding, the incidence of Bp infections is projected to rise [6]. Indeed, Queensland (Australia), has recently reported its worst year on record for melioidosis, with over 249 confirmed infections and 36 deaths linked to dispersal of the pathogen during flooding events (Queensland Health). While direct transmission between animals and humans has not yet been confirmed, growing concerns have emerged regarding potential transmission from pets, livestock or tropical animals to humans, either through contact with infected wounds or via shared exposure to contaminated environments [2,7]. Compounding these risks, Bp is naturally highly resistant to several antibiotic classes, and while frontline drugs such as meropenem, ceftazidime, and trimethoprim/sulfamethoxazole is still uncommon [8], emerging reports of resistance are increasing [9–12]. These clinical and epidemiological challenges highlight the urgent need for accurate diagnostics that account for the pathogen’s remarkable adaptability and diversity. A key yet often overlooked feature of Burkholderia species is their ability to undergo colony morphotype variation (CMV), a reversible process by which bacteria switch between distinct colony phenotypes [13]. This phenomenon reflects rapid adaptation to environmental stressors and is often associated with changes in outer membrane proteins, antimicrobial production, and virulence factors [14–18]. Mechanisms underlying CMV often include mutations in global regulators, two-component systems, genome reduction and duplication, bacteriophage integration, and DNA methylation (recently reviewed by Coulon and colleagues [13]). Bp is known to exhibit up to seven different macrocolony morphologies which can be modulated under laboratory conditions [14,18,19]. Importantly, CMV is not limited to adaptation in vitro as it also occurs during infection [20]. Approximatively 10% of 450 Bp clinical isolates produce mixed mucoid and non-mucoid CMV populations on blood agar [20]. In a long-term murine infection model, small colony variants (SCVs) were observed [21,22]. During human infection, differences in O-antigen lipopolysaccharides (LPS; [OPS]) production explains the mucoid phenotype (as observed on blood agar) even in the absence of mutations or altered expression of the wbiA O-antigen acetylase [20]. Additionally, genes within the LPS biosynthesis cluster are upregulated during persistent infection in mice [21,22]. The upregulation of the σ-54 dependent regulator yelR, is involved in the emergence of two reversible yellow Bp variants, which display enhanced resistance to hypoxic stress and increased colonization and persistence in the murine stomach [23]. These findings highlight that CMV can complicate both laboratory and clinical recognition of Bp. Distinguishing between true morphology variant and genetically distinct strains is particularly challenging, as both can present as colony diversity during culture. While investigating CMV within a cohort of Bp isolates [24] collected from clinical melioidosis cases at Townsville University Hospital (Australia) [25], we identified a polyclonal infection initially mistaken for colony morphotype variants. The apparent rough and smooth ‘variants’ were in fact two genetically distinct strains isolated from the same infection site. Such polyclonal Bp infection is rarely reported, with an apparent occurrence of 1.5% in a cohort of 133 patients when testing ten colonies from each samples [26]. However, Kaewrakmuk and colleagues reported that 22% of Bp clinical infections are polyclonal, involving two to three different sequence types (STs; [27]). Importantly, no prior study has conducted an integrated multi-omics analysis of the co-isolated Bp pathogen. Here, we present the first study combining genomic, proteomic, and phenotypic analyses of two co-infecting Bp strains from a melioidosis patient in Australia, which underscores the need to refine diagnostic awareness and methodologies to detect clinically relevant polyclonality. Materials and methods Ethical approval This study received ethical approval from the Royal Brisbane and Women’s Hospital Ethics Committee (LNR/2020/QRBW/65573), with site-specific authority obtained from the Townsville Hospital and Health Service and approval under the Queensland Public Health Act. This is a retrospective ethic approval from 1st January 1997–31st December 2020, and data were accessed/collected from December 2020 to April 2021. Patient consent was waived by the HREC. Colony morphology screening Bp TSV292 was, originally, isolated from a blood culture that tested positive for Bp. The blood culture was used to set up a purity plate, and the resulting growth was used to make a −80 °C glycerol stock. For this study, Bp TSV292 from the frozen glycerol stock was streaked onto LB agar plates supplemented with 0.01% Congo Red (CRLA) and incubated at 37 °C for two consecutive overnight periods. Subsequently, four colonies of each observed morphological variation were subjected to further investigation. Genomic analysis gDNA extraction. Using either gDNA spin or high molecular weight gDNA extraction kits (NEB), gDNA was extracted from multiple macrocolonies grown for three overnights at 37°C on CRLA. Short-read sequencing (Illumina) was conducted on all CMVs. Briefly, libraries were prepared using 1 ng of gDNA via the Nextera XT kit and sequenced using the NovaSeq XPlus platform (35). On select isolates, long-read sequencing (Oxford Nanopore Technologies) was implemented. Libraries were prepared using 400 ng gDNA with the SQK-NBD114.24 kit and sequenced using R10.4.1 flow cells on the GridION platform. Reads were base called using Dorado 7.6.7. Genome assembly. Nanopore and Illumina reads were filtered and trimmed using respectively nanofilt (v.2.8.0; [28]) and fastp (v0.24.1; [29]). Each set of Nanopore long reads were then assemble using autocycler tool (v0.4.0; [30]). The long-read consensus assemblies were polished with Illumina short read sequences using polypolish (v0.6.0; [31]) and then pypolca (v3.0.1; [32]). Finally, the obtained assembly was annotated using batka (v1.11; [33]). For the second CMV isolated from each isolate, Illumina short reads were assembled using unicycler short read assembler (v.0.5.1; [34]) generating contigs. Illumina sequencing coverage was ~ 67.5x and 68x for TSV292_1 rough and TSV292_2 smooth respectively. Nanopore sequencing coverage was ~ 568x and 2,941x for TSV292_1 rough and TSV292_2 smooth respectively. Genomic modification analyses. Each set of Illumina reads, belonging to the second CMV, were mapped on their respective first CMV assembly using snippy tools with haploid settings (v4.6.0; [35] available on Galaxy) to determine SNPs and indels, to confirm the results, the first CMV Illumina reads were also mapped onto their own assembly, resulting in showing no genomic variation. Genotyping and phylogeny analysis. Six thousand two hundred fifty-nine allelic profiles of 1,225 available Bp isolate genomes on pubMLST genomes database were retrieved and used to generate a distance phylogenetic tree with GrapeTree using allelic profile differences [36]. The resulting tree was generated using ggtree R package. PhyloSift v1.0.1 was used to resolve the subclade phylogeny of the two clusters (identified from the wgMLST clustering analysis) by computing a maximum-likelihood tree based on the 37 prokaryotic marker genes of each genome (available on pubMLST) using FastTree2.2 [37]. FigTree v1.4.4 was used to draw the unrooted phylogenetic trees and FastANI was used to identify the pairwise average nucleotide identity with the respective ST identified in this analysis. BRIG-0.95 [38] was used to map pairwise BLASTn alignment of selected genomes [39]. Prediction of antibiotic resistance genes. AMR gene orthologs present in genomes was identified using the CARD database [40] and outputs were filtered to tabulate data of candidates which had 100% coverage of subjects with at least 40% similarity. Antibiotic Resistance Detection and Prediction (ARDaP) tool was used to determined antibiotic resistance profile of both isolates [41]. Whole genome alignment. Both MAUVE [42] and LASTZ [43,44] tools were used to aligned TSV292_1 (rough) and TSV292_2 (smooth) together, using the default settings. To correct aligned genomes with LASTZ tool, the first residue numbers for each chromosome were changed as followed, to set up the same origin. For TSV292_1 rough contig 2 residue 1,249,185 became 1 while TSV292_2 (smooth) contig 1 was reversed and residue 285,486 became 1; TSV292_2 (smooth) contig 2 residue 490,391 became 1. Determination of unique and duplicated genes. The sequence of annotated genes from each genome were aligned to the other genome’s nucleotide sequences using BLASTn with the following parameters: -evalue 10 -outfmt 6 -num_threads 3 -max_target_seqs 1 -max_hsps 1 [39]. Hits with >90% sequence identity were retained and cross-analyzed with the corresponding results obtained from comparisons against Bp K96243. Finally, genes located within genomic regions identified as deleted or inserted by LASTZ were filtered out. Methylome analysis Pod5 files obtained from Nanopore sequencing were merged, using pod5 merge function and analyzed for DNA methylation motifs using the Dorado with both dna_r10.4.1_e8.2_400bps_hac@v4.3.0_6mA@v2, dna_r10.4.1_e8.2_400bps_hac@v4.3.0_5mC_5hmC@v1 models (https://github.com/nanoporetech/dorado). To identify the location and number of detected motifs, as well as the genes encoding DNA methyltransferases, the call_methylation (using default settings --min_strand_coverage 10, --methylation_confidence_threshold 0.66, --percent_methylation_cutoff 0.66, and --percent_cutoff_streme 0.9) and annotate_rm functions from MicrobeMod [45] were used. These tools were provided with the corresponding genome assembly “.fasta” and annotation “.gff3” files for each isolate. Proteomic analysis Bacterial growth condition. Individual colonies (three biological replicates) were picked and stabbed into CRLA plates and incubated at 37°C for three nights. The three resulting microcolonies were used for proteomic analyses. Protein extraction and peptide preparation. Bacterial cells in 1M Tris-HCL containing 1% SDS were sonicated in an ultrasonic bath YJ5120−1 (Labtex) for 3 minutes, followed shaking at 1,000 rpm at 95°C for 15 minutes on a Thermomixer Compact (Eppendorf). The mixture was allowed to cool down to room temperature and 30 µL was mixed with 270 µL of Buffer I (6 M guanidine chloride, 50 mM Tris pH 8.0, 10 mM DTT) and incubated at 30°C for 40 min. Following addition of 9 µL of 0.5 M iodoacetamide, the sample was incubated at 30°C for 50 min. The reduced and alkylated protein sample was transferred to a 10 kDa cut-off Amicon Ultra device (Merck) which was placed into a collection tube and centrifuged at 14,000 × g for 30 min. The flow-through from the column was removed and 300 µL of 100 mM ammonium bicarbonate was added to the column followed by centrifugation at 14,000 × g for 30 min. To digest proteins in the column, 130 µl of 100 mM ammonium bicarbonate containing 2 µg Trypsin was added. The column was incubated at 37°C for 24 h and then centrifuged in a new collection tube at 14,000 × g for 30 min. Fifty µL of water with 0.1% formic acid was then added to the spin column followed by centrifugation at 14,000 × g for 30 min to elute the remaining digested peptides. Enzymes and salts were removed using C18 ZipTips (Merck) following the manufacturer’s instructions and desalted peptides were eluted with 80% acetonitrile/0.1% formic acid into microcentrifuge tubes. Digested peptide samples were dried down using a vacuum concentrator (Concentrator plus, Eppendorf) and reconstituted with 50 μL water with 0.1% formic acid prior to LC-MS/MS analysis. LC-MS/MS analysis. The samples were chromatographically separated and resulting proteomics data was acquired using an Acquity M-class micro-LC system (Waters, USA) coupled with ZenoTOF 7600 LC-MS/MS system using the OptiFlow Turbo V ion source. (AB Sciex). Two µL of sample were loaded onto Micro TRAP C18 column (0.3 × 10 mm; Phenomenex) and washed for 10 min at 10 µL/min with 97% solvent A (water with 0.1% [v/v] formic acid) and 3% solvent B (99.9% [v/v] acetonitrile, 0.1% [v/v] formic acid). Liquid chromatography was performed at 5 µL/min using a 2.7 µm Peptide C18 160Å; (0.3 × 150 mm; Bioshell) column with the column oven temperature maintained at 40°C. The gradient started at 3% solvent B which was increased to 5% by 0.5 min, followed by an increase to 35% solvent B by 38.9 min and then another increase to 80% solvent B by 39 min. The column was washed with 80% solvent B for 3.9 min before equilibrating with 3% solvent B from 43 to 45 min. Data was acquired using Zeno SWATH DIA, using a 65 variable width SWATH windows. The TOF MS parameters were as follows: precursor mass range was 400–1500 m/z; declustering potential (DP) was set to 80 V and accumulation time was set at 0.25 s. The TOF MS/MS parameters were as follows: fragmentation mass range was set to 100–1500 m/z; with an accumulation time of 0.025s; fragmentation mode was set to CID with Zeno pulsing selected. The collision energy for the MS/MS acquisition was automatically adjusted according to the m/z and charge of the peptide. Data analyses. Raw label free quantification (LFQ) LC-MS/MS data were converted to.mzML files, using MS convert, to allow the data search using Fragpipe v22 [46]. Protein identification was conducted against the respective annotated proteomes using the DIA_SpecLib_Quant workflow, which builds a spectral library with MSFragger-DIA and performs quantification with DIA-NN. The output “diann-output.pg_matrix.tsv” was filtered to remove contaminants and retain proteins with at least two non-missing values for at least one group. Data was normalized using the variance stabilization normalization [47]. Proteins with two or more missing values in one group were categorized as “detected/not detected.” For proteins with a single missing value in one group, missing data were imputed using the mean of the other replicates in that group. Differential protein expression between groups was assessed using Welch’s t-test, with Benjamini–Hochberg correction applied to control the false discovery rate (adjusted p < 0.05) [48,49] (S5-S9 Tables). Proteomic representation. To assign homologous proteins and annotations between TSV292 rough, smooth and K96243 (Bp model), were assigned as described in the “determine the number of unique genes” method. Clustering of orthologous groups (COGs) for annotated proteins were determined using EggNOG tool v5 [50]. To represent the data in a volcano plot, detected/not detected data were imputed using the lower normalized Log2 value for intensity with an imputed adjusted pvalue randomly assigned between 0.01 and 0.00001. Enrichment analysis was done using a Fisher exact test based on the COGs, using Claude AI for the script. Phenotypic assays Production of virulence factors. Individual colonies (four biological replicates) were picked and stabbed into LB agar plate containing 1.5% skimmed milk (assessing proteolytic activity; [51]), Cas assay plates made with 10X chelated LB [24]; 0.5 g/L yeast extract supplemented with 4g/L D-mannitol (YEM) and agar (assessing mucoidy; [52]) and Columbia horse blood agar plate (assessing hemolysis activity; [53]). Plates were incubated at 37°C for 3 days. Inhibition zones were measured and analysed statistically. Data normality was assessed using the Shapiro–Wilk test, followed by either a Wilcoxon rank-sum test or a t-test to compare the phenotypic results between TSV292_1 (rough) and TSV292_2 (smooth). The reference isolate Bp K96243 was not included in our tests as, phenotypes are strain specific. Antimicrobial sensitivity assay. Individual colonies were resuspended in 0.9% NaCl solution to obtain a turbidity of 0.5–0.63 McFarland. Bacterial suspensions were then spread onto Muller Hinton II agar plates and incubated overnight at 37°C with 0.002–32 µg/mL Meropenem (MEM) ETEST (Biomérieux), 10 µg Ceftazidime (CAZ) and 25 µg Sulfamethoxazole-Trimethoprim (TMP-SMX) Antimicrobial Susceptibility discs (Oxoid). For the discs assay, antimicrobial susceptibility was determined by following the recommendation from EUCAST(v15; https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_15.0_Breakpoint_Tables.pdf). For CMVs from the same isolate showing considerable visual changes in antibiotic susceptibility, three biological replicates were conducted on independent days, and the average of inhibition data were used to determine their susceptibility characteristic. Data normality was assessed using the Shapiro–Wilk test, followed by either a t-test to compare the phenotypic results between TSV292_1 (rough) and TSV292_2 (smooth). The reference isolate Bp K96243 was not included in our tests as, phenotypes are strain specific. Results Isolation of TSV292_1 rough and TSV292_2 smooth colony morphotypes In Burkholderia, CMV typically occurs upon removal of environmental pressure or during aging [14,18]. Because selective media for Burkholderia pseudomallei (Bp) often contain antibiotics that can induce colony morphology changes (e.g., the wrinkled phenotype in Bp), the clinical isolate TSV292 was streaked directly onto LB agar supplemented with 0.1% congo red (CRLA) from a −80 °C glycerol stock to facilitate CMV distinction. On this medium, a mixed population was observed, consisting of flat colonies with a red center (type RI) and smoother, raised colonies (type SI) (Fig 1A). The rough and smooth phenotypes were confirmed by isolating single colonies and subculturing them on CRLA or Ashdown agar (Fig 1B). Both media yielded CMV types consistent with those previously reported for isolate TSV82 [24]. Colony morphologies of the two Bp strains isolated from TSV292. A) −80°C glycerol stock streak on CRLA, white arrow indicates the presence of second colony morphotype corresponding to TSV292_2 smooth strain. B) Colony morphology of both isolates after 3-days growth on both CRLA and Ashdown agar. Importantly, this initial observation suggested classic CMV, highlighting the risk of misclassifying polyclonal infections as morphotypic variation during standard diagnostic workflows. Polyclonal strains masquerading as CMV in melioidosis infection Genomic variation, master regulator expression or epigenetics are known drivers of CMV in Burkholderia; hence, we first investigated whether SNPs or insertion and deletions (indels) accounted for the distinct morphologies of TSV292. Illumina reads from TSV292 rough were mapped against the assembled genome of TSV292 smooth, using Snippy [35], which revealed 23,229 genomic modifications (S1 Table). This unexpectedly high level of variation suggested that the two morphotypes were polyclonal rather than colony morphotype variants of the same isolate. Multi-locus sequence typing (MLST) further supported this conclusion: the rough isolate was identified as ST-2319 (TSV292_1; PubMLST sample ID:7631; previously reported by Gassiep and colleagues [25]), whereas the smooth isolate represented a novel sequence type (TSV292_2; PubMLST sample ID:7519; ST-2323) (S2 Table). These findings demonstrate that rough and smooth variant colonies can mask genetically distinct strains, emphasizing the need for genomic-level analyses to accurately identify co-infections in melioidosis. Because simultaneous infection with multiple distinct Bp clones from the same patient is considered rare [26,27], we further investigated the genomic and proteomic profiles of these isolates to gain a deeper understanding of their divergence. Comparative analysis of Bp ST-2319 and ST-2323 The average nucleotide identity (ANI) between the two genomes was 99.4%. TSV292_1 (rough) had a genome size of 7,262,464 bp with a GC content of 68.1%, while TSV292_2 (smooth) had a genome size of 7,352,845 bp with a GC content of 68.0%. Clustering analysis of whole-genome MLST (wgMLST) based on 6,259 allelic profiles of 1,225 available isolate genomes in the PubMLST database (August 2025) revealed two distinctly separate groups (Fig 2A). Maximum-likelihood phylogenetic analysis showed that TSV292_1 rough clustered with Bp strains previously isolated from melioidosis patients admitted at Townsville University Hospital between 1997 and 2020 [25], whereas TSV292_2 smooth was more closely related to Bp strains isolated in Cambodia (Fig 2B). TSV292_1 rough and TSV292_2 smooth shared >99.2% ANI with their closely related Bp isolates but also contain variable regions representing strain-specific regions (S1 Fig). Two distinct Bp strains co-infecting the same patient suffering from melioidosis in 2017. A) Circular phylogenetic tree constructed using GrapeTree software showing relationships between isolates based on wgMLST allelic profiles. The tree represents a minimum spanning tree where branch lengths correspond to the number of allelic differences between isolates across genome loci. Each tip represents an individual isolate, with closer proximity indicating greater genetic similarity. Two reference strains are highlighted: TSV292_1 rough (blue) and TSV292_2 smooth (green). The scale bar represents 1 allelic difference. Isolates are colored by source as indicated in the legend. The analysis included 1,225 isolates characterized using 6,259 loci from the wgMLST scheme. B) Zoomed on closest isolated for both TSV292_1 rough (blue, right top panel) and TSV292_2 smooth (green, right bottom panel), using maximum likelihood phylogenetic analysis, using Fasttree, based on closest relative genomes. Whole-genome alignment of the TSV292 co-isolates, using MAUVE algorithm [42], revealed synteny across the locally co-linear blocks and highlight genomic rearrangements likely as a result of recombination events in both chromosomes (S2 Fig). Alignment using the LASTZ tool [43,44], further revealed divergence between TSV292_1 rough and TSV292_2 smooth across several genomic regions, totalling 240,390 bp and 357,022 bp, respectively. In addition, 93 and 74 duplicated genes were identified outside these regions, which likely account for the observed difference in genome size (S3 and S4 Figs). In TSV292_1 rough, regions absent in TSV292_2 smooth included: (i) a 7,465 bp segment containing a type II restriction enzyme and DNA Methyltransferase (DNA MTase) predicted to be responsible for m5C methylation on GTCGAC pattern (TSV292_R_RS_00500–00501) surrounded by IS3 family transposase; (ii) a 36,612 bp region including predicted phage elements and a singleton DNA MTase (TSV292_R_RS_02319); and (iii) a 61,103 bp region with 26 putative transposases consistent with lateral gene transfer, that also encoded the Bp adhesion (bpa) gene cluster—implicated in bacterial attachment and immune evasion [54] —suggesting functional differences in host interaction and pathogenic potential. On chromosome 2 TSV292_1 rough carried a 43,430 bp region with an integrase (TSV292_R_RS_04679) and phage elements; a 36,084 bp region rich in transposases and viral genes, including a type III restriction DNA methyltransferase (TSV292_R_RS_03252; S6 Table); a 21,283 bp region containing a putative origin of replication with a PAAR gene and a type III restriction DNA MTase (TSV292_R_RS_03525) suggestive of plasmid integration; and a 43,340 bp region containing phage elements (S3 and S4 Tables). By contrast, TSV292_1 rough lacked multiple phage-associated and transposon-rich regions present in TSV292_2 smooth, including loci encoding type II, III, and IV restriction MTases predicted to modify m4C, m5C, and m6A motifs (e.g., TSV292_RS_03205, TSV292_RS_03345, TSV292_RS_15530, TSV292_RS_15535, TSV292_RS_18580, TSV292_RS_26185; S3-S6 Tables). Differences also extended to the flagellar biosynthesis cluster, where the two genomes displayed altered gene order (S5 Fig). As deletion of genomic regions commonly occurs during bacterial adaptation and host evolution [55], we next examined whether each genome carsried unique genes. To assess this, annotated genes from each genome were aligned against the other genome’s nucleotide sequences using BLAST, retaining hits with >90% sequence identity, and cross analysed the results of both genomes blast against K96243. From this analysis, only one unique gene was identified in TSV292_1 rough (TSV292_R_RS_00840), encoding a hypothetical protein. These findings were consistent with the results of our LASTZ analysis (S3 and S4 Figs). Taken together, these results indicate that divergence between both strains involved acquisition or loss of phage elements, transposons, plasmid-associated regions, and DNA methylation systems. Such changes not only underscore the genome plasticity of Bp but also suggest functional consequences for immune evasion, horizontal gene transfer, and regulation of surface structures critical for infection. Multi-omics approaches are therefore essential to resolve polyclonal infections and guide treatment strategies. Distinct phenotypes in antibiotic sensitivity, mucoidy, hemolysis, siderophore production and proteolytic activity To confirm the proteomic analyses, phenotypic assays assessing virulence-related traits, including antibiotic susceptibility, were performed (Table 1) and revealed notable differences between the two isolates. TSV292_2 smooth exhibited a higher resistance to trimethoprim-sulfamethoxazole (TMP-SMX; 5.32 ± 1.15 mm against 23.88 ± 5.79 mm for TSV292_1 rough), with no apparent difference in predicted antibiotic resistance by ARDaP (S7 and S8 Tables; [41]), and displayed increased mucoidy, consistent with higher exopolysaccharide (EPS) production when grown on YEM agar. In contrast to TSV292_1 rough, the TSV292_2 smooth strain lost its ability to lyse red blood cells and lacked proteolytic activity. Interestingly, both isolates produced a smooth-edged sector around the main colony when grown on Ashdown and blood agar, suggesting an active role in CMV emergence (Fig 3). Differences in antibiotic sensitivity and production in virulence factors underscore that genomic analyses alone could mislead clinicians regarding virulence potential and drug susceptibility, highlighting the need to integrate molecular and phenotypic analyses in melioidosis diagnostics. 10.1371/journal.pone.0338333.t001Table 1Phenotypic profile of both Bp TSV292_1 rough and TSV292_2 smooth.IsolateColony morphologyAntibiotic Susceptibility testMEMCAZTMP-SMXMucoidyHemolysisProteolytic Activity (cm2)Siderophore production (cm2)TSV 292Strain 1 (rough)SII+beta3.26 ± 0.75**0.399 ± 0.093**Strain 2 (smooth)SIR⫮++gamma0.88 ± 0.091.811 ± 0.33EUCAST: S = Susceptible; I = Susceptible increased exposure; R = Resistant; Meropenem (MEM): S≤2; R > 2; Ceftazidime (CAZ; disk 10 µg): S≥50mm; R < 18mm; Trimethoprim-Sulphamethadoxone (TMP-SMX; disk 1.25–23.75 µg): S≥50mm; R < 17mm;“⫮” represent a TMP-SMX susceptibility statistically different between TSV292_1 and TSV292_2 using a ttest;Mucoidy: + = mucoid; ++ = more mucoid;Hemolysis at 8 days: beta = complete lysis of red blood cell; gamma = no lysis;Proteolytic activity and Siderophore production: average ± stand deviation;“**” represent statistical significance (ttest) in both proteolytic activity or siderophore production with a pvalue comprised between 0.05 and 0.01 when comparing both TSV292_1 and TSV292_2. Phenotypic profile of both Bp TSV292_1 rough and TSV292_2 smooth. EUCAST: S = Susceptible; I = Susceptible increased exposure; R = Resistant; Meropenem (MEM): S≤2; R > 2; Ceftazidime (CAZ; disk 10 µg): S≥50mm; R < 18mm; Trimethoprim-Sulphamethadoxone (TMP-SMX; disk 1.25–23.75 µg): S≥50mm; R < 17mm; “⫮” represent a TMP-SMX susceptibility statistically different between TSV292_1 and TSV292_2 using a ttest; Mucoidy: + = mucoid; ++ = more mucoid; Hemolysis at 8 days: beta = complete lysis of red blood cell; gamma = no lysis; Proteolytic activity and Siderophore production: average ± stand deviation; “**” represent statistical significance (ttest) in both proteolytic activity or siderophore production with a pvalue comprised between 0.05 and 0.01 when comparing both TSV292_1 and TSV292_2. CMV emergence from both isolates occur after 8 days of growth on various media. White arrows indicate variants emergence from the main colony when culture on different media to study bacterial phenotypes. Despite being two isolates, proteomics profiles characterise them as rough and smooth Bp CMV morphotypes Proteomic profiling confirmed that the two isolates correspond to the expected profiles of rough and smooth Bp morphotypes, with differences in virulence- and resistance-associated pathways (Fig 4). In total, 1,015 proteins were differentially produced between the two isolates (Fig 4A; S9 and S10 Tables). Proteomic profiling of both TSV292_1 rough and TSV292_2 smooth isolates. A) Volcano plot representing the significant abundance changes in proteins between both isolates. B) Enrichment analysis of virulence factors and COGs reflecting the proteins changes. In the TSV292_2 smooth strain, proteins associated with antimicrobial gene cluster biosynthesis were more abundant or exclusively detected. These included those involved in the production of pyochelin, malleobactin, malleilactone, bactobolin, and syrbactins [56–58]. Notably SyrC/GlbC, part of the syrbactin cluster, is also known to influence Bp survival and replication within immune cells [56,59]. Additionally, proteins related to flagellar biosynthesis, the quorum sensing system 2 (BpsR2; belonging to the bactobolin biosynthesis cluster), and the Hmq system, which produces HMAQs with antimicrobial activity and known interaction with QS systems, were more abundant or exclusively detected [58,60,61]. In contrast, the TSV292 rough morphotype showed higher abundance or exclusive detection of proteins involved in exopolysaccharide (EPS) production, type III O-polysaccharide (OPS) synthesis, DNA methyltransferase (MTase) responsible for the CACAG methylation motif, the quorum sensing system 3 (BpsI3/BpsR3), and the master regulator ScmR (Fig 4B). Proteins from antibiotic resistance genes [12,41,62,63], predicted using the CARD database (S11 Table; [40]), were generally not detected or detected at lower abundance in TSV292_2 smooth compared with the rough isolate (Table 2). This includes both AmrR, the TetR family transcriptional regulator that controls the expression of the AmrAB-OprA efflux pump, and BpeT, the transcriptional regulator of the BpeEF-OprC efflux pump, potentially explaining the observed TMP-SMX resistance in the smooth strain in Table 1 [41]. These results indicate a difference in adaptations between the two strains, with TSV292_2 smooth adopting an environmental-like smooth form and TSV292_1 rough displaying a pathogenic rough form [16,58]. Proteomic profiling further demonstrates that diagnosis based solely on colony morphology—or even coupled with genomic data—may fail to capture the full functional diversity of co-infecting strains. Detailed molecular characterization of protein expression can uncover hidden differences in virulence, antimicrobial production, and resistance mechanisms, providing a more reliable foundation for diagnostics and treatment decisions. 10.1371/journal.pone.0338333.t002Table 2Significance differences in the abundance of protein involved in antibiotic resistance.Protein in Bp K96243Protein in TSV292 RProtein in TSV292 SGene NameProductMean intensity in TSV292_1 rough (Log2)Mean intensity in TSV292_2 smooth (Log2)Differential abundance TSV292_1 rough vs TSV292_2 smooth (Log2)pvalue (ttest)Adjusted pvalue (fdr = 0.01)SignificanceResistanceReferenceBPSL1440RS_05656RS_24985hypothetical protein14.412.2−2.1780.0070.019Lower abundance in roughSXT[62]BPSL1357RS_04972RS_21485 folP dihydropteroate synthase11.313.01.7290.0010.006Lower abundance in roughSXT[63]BPSS0946RS_02455RS_12455 penA beta-lactamase precursor12.514.41.9030.0010.005Lower abundance in roughCAZ[62]BPSL0814RS_04343RS_18740 bpeA RND family acriflavine resistance protein A13.915.71.7780.0000.002Lower abundance in roughMEM[62]BPSS1898RS_01406RS_02545 fadH 2,4-dienoyl-CoA reductaseNA9.1NANANANot detected in roughMEM[62]BPSL1805RS_05301RS_23130 amrR TetR family regulatory proteinNA10.0NANANANot detected in roughMEM[12,62]BPSS0290RS_00441RS_08815 bpeT LysR family transcriptional regulatorNA10.9NANANANot detected in roughMEM/CAZ/SXT[12,41,62]BPSS1269RS_02119RS_00900 syrC/glbC peptide synthase/polyketide synthaseNA12.5NANANANot detected in roughAMC/CAZ[62]BPSS1095RS_02298RS_13015heat-shock chaperone proteinNA13.0NANANANot detected in roughSXT[62]BPSS1654RS_01708RS_01070cytochrome P4509.4NANANANANot detected in smoothAMC[62]BPSL0812RS_04342RS_18735 bpeR TetR family regulatory protein10.5NANANANANot detected in smoothMEM[12]BPSS2246RS_01043RS_06515sensor kinase/response regulator fusion protein11.2NANANANANot detected in smoothSXT[62]BPSS1197RS_02196RS_00505non-ribosomal peptide synthase12.3NANANANANot detected in smoothCAZ/MEM/SXT[62]BPSL0816RS_04346RS_18755 oprB outer membrane efflux protein13.6NANANANANot detected in smoothCAZ[62]BPSL2553RS_02674RS_28050siderophore receptor protein10.513.42.8500.0070.018Lower abundance in smoothCAZ/MEM[62]RS_01304RS_05215 blaOXA OXA-42 family class D beta-lactamaseNATET*NA: not applicable. Significance differences in the abundance of protein involved in antibiotic resistance. *NA: not applicable. Methylome showed no overall difference in methylated sites between TSV292 rough and smooth Predicted restriction enzyme methylated motifs were consistent with the one described by Nandi and colleagues [64] (S7 and S12 Tables). Given the observed difference in abundance of the DNA MTase responsible for the CACAG methylation motif (TSV292_R_RS_03660/03661 in rough colony morphotype TSV292_RS_15080/15085 in the smooth, for which proteins were not detected in TSV292_2 smooth while detected in TSV292_1 rough isolates), we further investigated the methylome profiles of both isolates (S12 Table). Despite the presence of distinct abundance of DNA MTases, no significant differences were observed in methylated sites across the genomes of TSV292 rough and smooth for motifs CACAG, GTWWAC and CATCAG. Despite strain-specific differences in DNA methyltransferase expression, methylation profiles alone may not distinguish co-infecting strains. Discussion Melioidosis causes an estimated 179,000 cases and 90,000 deaths worldwide each year [5]. As Bp is intrinsically resistant to antibiotics, treatment relies on last-resort agents. Emerging resistance remains a major concern [9–11]. While simultaneous polyclonal Bp infections are rarely reported [26,27], here we report the first such case in Queensland, isolated from a patient swab in 2018. A key diagnostic challenge revealed by this study is that polyclonality can be mistaken for CMV. Current diagnosis workflows—typically involving (1) single-colony purification with selection of a characteristic wrinkled morphotype on selective media or blood agar; (2) microscopy targeting DNA or RNA sequences using fluorescence in situ hybridization or immunofluorescence; (3) molecular diagnostics such as conventional PCR or sequencing; (4) serodiagnostic tests, including ELISA or agglutination assays; and (5) imaging and spectrometry approaches, including CT or MRI of the patient and MALDI-TOF for bacterial isolates [4]—cannot reliably distinguish Bp isolates at the strain level, as these methods generally operate at the genus or species level. Bacterial polyclonality further complicates these diagnostic approaches. PCR-based assays (qPCR and Illumina sequencing) fail to identify novel variant strains, resulting in amplification bias toward the dominant genotype or a de novo hybrid [65]. Misidentification of clonal variants can also stem from mixed DNA templates from polyclonal infections. Serological tests may be influenced by cross-reactive antibodies, as infections with multiple strains can create unclear profiles that hinder interpretation. For instance, if the main strain has a different capsular polysaccharide type, antibody detection might drop below the assay’s limit, resulting in false negatives or inconclusive outcomes. Moreover, most diagnostic tests are typically performed on a single pure colony rather than multiple-colonies, making it difficult to distinguish true CMV from mixed-strain infections. This challenge is especially evident when morphological differences are assumed to reflect common CMV, or when a less dominant strain is present that morphologically closely resembles the dominant colony. Overall, this diagnostic blind spot risks underestimating strain diversity and may lead to inappropriate clinical decisions or treatment failures [13]. Because Burkholderia species exhibit extensive colony morphotype plasticity with a particular mucoid/wrinkled colony morphotype [14,18,20], relying on phenotypic assessment alone can mask genetically distinct pathogens. In this case, two morphotypes that appeared as rough and smooth variants on CRLA and as mucoid/wrinkled on Ashdown selective medium. The different morphotypes were in fact distinct strains rather than in-host genetic variants that evolved by micro-evolutionary events or products of sample contamination or CMV of a single isolate. Importantly, our experimental procedures were conducted independently from the initial identification of TSV292_1 (rough morphotype) as a novel ST2319 [25]. The smooth isolate, TSV292_2, not only had a distinct ST but also had > 23,000 genomic nucleotide differences, including deletion of multiple genomic regions ranging from ~7–61 kb. While genomic deletions during host adaptation are common, two Bp strains isolated ~12 years apart from a single patient with chronic infection were previously shown to differ by only 23 SNPs [55,66]. Therefore, in-host evolution remains unlikely. Cross-contamination of the specimen in the diagnostic laboratory is possible; however, as no other TSV isolates in the strain collection share the same ST as TSV292_2, it is an unlikely but possible event. We also investigated DNA methylation, given its known role in CMV and intraspecies recombination [67]. While global methylation patterns appeared similar between the isolates, the absence of detectable DNA MTases by LC-MS/MS in the smooth morphotype mirrored our prior findings in smooths CMVs [24]. This could reflect biological differences in MTase stability or abundance but may also stem from limitations of single-replicate methylome analysis in detecting subtle variation. By integrating genomic, proteomic, and phenotypic analyses, we demonstrate how distinct co-infecting strains can mimic CMV, with smooth and rough colony morphotypes differing in the production of proteins involved in virulence, stress tolerance, drug responses and adaptation—features with direct implications for patient management. A clear example is the trimethoprim-sulphamethadoxone susceptibility test assay. Disk diffusion assays consistently revealed differential susceptibility profiles across all technical and biological replicates, confirming the reliability of our findings under the conditions we used. Treatment could preferentially eliminate the more sensitive isolate and potentially allow proliferation of the resistant strain and lead to treatment failure if not paired with other effective antibiotics. While genomic analysis using the ARDaP tool did not reveal any antibiotic resistance prediction for both isolates, this highlights that genomic data alone may underestimate functional antibiotic resistance. Our findings also underscore the vulnerability of outbreak tracing and marker gene based phylogenomic inference to hidden co-infection. Whole genome based clonal verification should therefore precede evolutionary or epidemiological analyses of Bp. High-quality, closed genomes from long-read assemblies, combined with read-level deconvolution using short-read sequencing, should be standard practice before calling variants. However, if identification of Bp is restricted to an analysis of a single colony during diagnosis, polyclonality will be missed. Covert polyclonality, rather than ultra-rapid evolution, may significantly contribute to the observed genomic diversity. Therefore, enhancing diagnostic procedures by increasing the number of colonies selected and analysed, including those showing CMV, is crucial for Bp. Screening multiple colonies has allowed studies in Thailand to successfully identify polyclonal infections with prevalence reaching up to 22% [26,27]. Furthermore, this strain diversity was associated with variation among isolates from related environmental sources [27]. These findings suggest that, in addition to improving diagnostic methods, adopting a One Health approach—characterising the diversity of Bp populations in soil and in animals—would greatly improve surveillance efforts and our understanding of infection dynamics [27,68]. Ultimately, this work highlights the urgent need for strain-level diagnostic methods that combine multi-omics and phenotypic data. Developing comprehensive reference databases of these profiles will allow comparative tools to assist in diagnosis, treatment, and surveillance. These advancements will not only enhance patient outcomes but also provide more precise epidemiological insights, deepening our understanding of Bp biology. Supporting information Genome alignment of TSV292_1 (rough) and TSV292_2 (smooth) with their respective closest isolates genomes. (PDF) MAUVE alignment of both TSV292_1 (rough) and TSV292_2 (smooth) against each other. The red line delimits both chromosomes in each genome. Contig 1 is one the left and contig 2 is on the right. Each color corresponds to an identical region in both genomes. (PDF) Genome alignment of TSV292_2 (smooth) on TSV292_1 (rough) using LASTZ alignment tool. Forward alignments between the reference TSV292_1 (rough) contig 1 (A) and contig 2 (B) (x-axis) and TSV292_2 (smooth) query (y-axis) genomes are shown in blue, indicating regions of conserved synteny in the same orientation. Alignments in red represent sequences aligned in the reverse-complement orientation, corresponding to inverted segments relative to the reference. Gaps with no alignment indicate regions unique to one genome, missing from the other, or below the similarity threshold for alignment. (PDF) Genome alignment of TSV292_1 (rough) on TSV292_2 (smooth) using LASTZ alignment tool. Forward alignments between the reference TSV292_2 (smooth) contig 1 (A) and contig 2 (B) (x-axis) and TSV292_1 (rough) query (y-axis) genomes are shown in blue, indicating regions of conserved synteny in the same orientation. Alignments in red represent sequences aligned in the reverse-complement orientation, corresponding to inverted segments relative to the reference. Gaps with no alignment indicate regions unique to one genome, missing from the other, or below the similarity threshold for alignment. (PDF) Highlight of the order of genes with an identified as flagellar product. A) TSV292_2 (smooth) genome. B) TSV292_1 (rough) genome. (PDF) Genomic variation and SNPS between TSV292 rough and smooth colonies. (XLSX) Bp isolates used to generate MLST phylogenic tree. (XLSX) Genomic region different between TSV292_1 (rough) and TSV292_2 9smooth) isolates. (XLSX) Predicted genomic islands in TSV292_1 (rough) using Island4 viewer tool. (XLSX) Predicted genomic islands in TSV292_2 (smooth) using Island4 viewer tool. (XLSX) Genes predicted as DNA Mtases in TSV292 rough and smooth. (XLSX) Antibiotic resistance profile of TSV292_1 rough. (XLSX) Antibiotic resistance profile of TSV292_2 smooth. (XLSX) Proteomic raw datasearch for TSV282 rough and smooth isolates with homology to Bp K96243. (XLSX) Proteomic analysis comparing both TSV292_1 rough and TSV292_2 smooth isolates with homology to Bp K96243. (XLSX) Antibiotic resistance gene prediction. (XLSX) DNA Methylation prevalence in TSV292 rough and smooth. (XLSX) 14 Oct 2025 Dear Dr. Coulon, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Nov 28 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, William C. Nierman, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. 3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 4. Thank you for stating the following in the Acknowledgments Section of your manuscript: This work was supported by AIMI and UTS Faculty of Science seed funds to Dr Pauline M.L. Coulon, UTS Strategic Research Accelerator funding (SRA 2726229) to Prof Garry S.A. Myers and EL2 Investigator grant from the NHMRC (APP2033851) to Dr Patrick N.A. Harris. Experimental work was done at UQCCR which would not have been possible without the ISME scholar funding awarded to Dr Pauline M.L. Coulon. P.M.L.C: Concept and visualization, Funding, Experimental work; K.M: Experimental work and reviewing, P.R.C: Genomic comparison; M.P and J.T: DNA libraries and sequencing; A.L, E.R and S.R: sample preparation and LCMS runs for the proteomic experiment; I.G & P.N.A.H: Reviewing and Funding; G.S.A.M: Reviewing and Funding. We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: This work was supported by AIMI and UTS Faculty of Science seed funds to Dr Pauline M.L. Coulon, UTS Strategic Research Accelerator funding (SRA 2726229) to Prof Garry S.A. Myers and EL2 Investigator grant from the NHMRC (APP2033851) to Dr Patrick N.A. Harris. Experimental work was done at UQCCR which would not have been possible without the ISME scholar funding awarded to Dr Pauline M.L. Coulon. Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 5. Please ensure that you refer to Figure 4 in your text as, if accepted, production will need this reference to link the reader to the figure. 6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 7. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set. Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file. Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data ) and in the following article: http://www.bmj.com/content/340/bmj.c181.long. 8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments : While the paper strongly supports the conclusion that two distinct genetic isolates are characterized as distinct genetic isolates in the culture collection clinical sample, the author does not address alternative explanations for the presence of the two strains. such as sample contamination, within host divergent evolution, or other possibilities. The author needs to address the concerns and suggestions made by the reviewers. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: N/A Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: The authors report two Burkholderia pseudomallei strains isolated from a single patient at a hospital in Townsville and interpret their findings as evidence of co-infection. This is an interesting and potentially important observation with implications for both the diagnosis and treatment of B. pseudomallei. However, the evidence as presented does not fully rule out alternative explanations, such as within-host divergent evolution or laboratory contamination. To substantiate the conclusion that these strains represent a true co-infection, further clarification is needed. In particular: 1. From which patient samples were the two strains isolated? Were they derived from the same specimen or from distinct sources? 2. How many independent isolates (colonies) of each strain were recovered? 3. Based on 16S rRNA gene sequences, how distinct are the two strains? 4. From whole-genome sequencing, how extensive are the differences between the strains? Are there genes or long sequence regions unique to one strain, beyond mutations or mobile element–associated insertions/deletions consistent with divergence from a common ancestor? More specifically, what accounts for the larger genome size of TSV292_2 compared with TSV292_1, and does TSV292_1 retain any unique sequences despite its smaller genome? 5. What is the likelihood that one strain (TSV292_1) is closely related to a previously isolated Townsville University Hospital strain? Could this reflect contamination from a preserved isolate rather than both strains representing true infection? Without addressing these points, the conclusion of co-infection remains plausible but not definitive. Reviewer #2: Dear Editor, This manuscript reports the co-isolation of two genetically distinct Burkholderia pseudomallei strains (ST-2319 and ST-2323) from a single melioidosis patient in Townsville, Australia. Using an integrated multi-omics approach (Illumina and Nanopore genome sequencing, proteomics via ZenoTOF 7600 LC-MS/MS, and phenotypic assays), the authors demonstrate that what initially appeared as colony morphotype variation (CMV) actually represented a true polyclonal infection. The work highlights the diagnostic challenges posed by such cases and suggests that standard laboratory workflows may underestimate strain diversity in clinical B. pseudomallei isolates. This is a technically strong and novel contribution to melioidosis research. It fits PLOS ONE’s scope for methodological rigor and open data sharing. Here are some comments and suggestions: Methods clarity: - Specify sequencing coverage, read depth, and methylation-calling thresholds used for Nanopore data. - Confirm whether proteomic and phenotypic assays were performed in biological triplicates or single replicates. - Indicate if any of the reference strains (e.g., B. pseudomallei K96243) was included in phenotypic assays; if not, explain why. Additional discussions: - Expand the discussion to address how polyclonality could influence antibiotic therapy outcomes, especially regarding the TMP-SMX resistance observed in the smooth isolate. - Discuss potential diagnostic challenges for PCR, MALDI-TOF, and serological assays when polyclonal infections occur. - Soften the statement “covert polyclonality rather than ultrafast evolution is a major driver…” to a more cautious phrasing (e.g., “may contribute significantly to observed genomic diversity”). - Consider including additional references discussing the prevalence of polyclonal infections, such as, Kaewrakmuk et al PLoS Negl Trop Dis . 2024 Aug 22;18(8):e0012444, when multiple bacterial colonies were selected for genotypings. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Heenam Stanley Kim Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. 16 Nov 2025 Response to Editor and Reviewers’ comments Firstly, we would like to thank both the Editor and Reviewers for providing valuable feedback, which have improved the manuscript quality. We have addressed and responded to the comments below: Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdfand https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf Response: The reviewed manuscript is formatted with the PLOS ONE's style requirements. 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. Response: Patient consent was waived by the HREC. 3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. Response: Thank you for pointing out the mistake. The correct grant numbers were provided prior to resubmission. 4. Thank you for stating the following in the Acknowledgments Section of your manuscript: This work was supported by AIMI and UTS Faculty of Science seed funds to Dr Pauline M.L. Coulon, UTS Strategic Research Accelerator funding (SRA 2726229) to Prof Garry S.A. Myers and EL2 Investigator grant from the NHMRC (APP2033851) to Dr Patrick N.A. Harris. Experimental work was done at UQCCR which would not have been possible without the ISME scholar funding awarded to Dr Pauline M.L. Coulon. P.M.L.C: Concept and visualization, Funding, Experimental work; K.M: Experimental work and reviewing, P.R.C: Genomic comparison; M.P and J.T: DNA libraries and sequencing; A.L, E.R and S.R: sample preparation and LCMS runs for the proteomic experiment; I.G & P.N.A.H: Reviewing and Funding; G.S.A.M: Reviewing and Funding. We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: This work was supported by AIMI and UTS Faculty of Science seed funds to Dr Pauline M.L. Coulon, UTS Strategic Research Accelerator funding (SRA 2726229) to Prof Garry S.A. Myers and EL2 Investigator grant from the NHMRC (APP2033851) to Dr Patrick N.A. Harris. Experimental work was done at UQCCR which would not have been possible without the ISME scholar funding awarded to Dr Pauline M.L. Coulon. Please include your amended statements within your cover letter; we will change the online submission form on your behalf. Response: The statement has been reviewed and included into the cover letter as followed: “This work was supported by the funding AIMI and UTS Faculty of Science seed fundings hold by Dr Pauline M.L. Coulon, the strategic research accelerator funding (SRA 2726229) hold by Prof Garry Myers and EL2 Investigator grant from the NHMRC (APP2033851) hold by Dr Patrick N.A. Harris. Royal Australasian College of Physicians Queensland Regional Committee Research Development Grant hold by Ian Gassiep allowed the collection and storage of Bp isolates. Experimental work was done at UQCCR which would not have been possible without the ISME scholar funding awarded to Dr Pauline M.L. Coulon”. 5. Please ensure that you refer to Figure 4 in your text as, if accepted, production will need this reference to link the reader to the figure. Response: Figure 4 is included in the proteomic result section and can be found at lines 429 and 447. 6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. Response: Captions of supporting information are provided at the end of the manuscript for both supplementary figures and tables. 7. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set. Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file. Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data) and in the following article: http://www.bmj.com/content/340/bmj.c181.long. Response: Our data do not contain any personal information. 8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Response: As suggested by Reviewer 2, a relevant missing article has been cited and included in the revised manuscript. Additional Editor Comments : While the paper strongly supports the conclusion that two distinct genetic isolates are characterized as distinct genetic isolates in the culture collection clinical sample, the author does not address alternative explanations for the presence of the two strains. such as sample contamination, within host divergent evolution, or other possibilities. The author needs to address the concerns and suggestions made by the reviewers. Response: Thank you for your valuable comment, which aligns with Reviewer 1’s feedback. We have included alternative explanations for the presence of the two strains in the Discussion section, starting at line 510. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer #1: The authors report two Burkholderia pseudomallei strains isolated from a single patient at a hospital in Townsville and interpret their findings as evidence of co-infection. This is an interesting and potentially important observation with implications for both the diagnosis and treatment of B. pseudomallei. However, the evidence as presented does not fully rule out alternative explanations, such as within-host divergent evolution or laboratory contamination. To substantiate the conclusion that these strains represent a true co-infection, further clarification is needed. In particular: 1. From which patient samples were the two strains isolated? Were they derived from the same specimen or from distinct sources? Response: Thank you for your questions. Our study is based on the isolation of two different morphotypes from the same glycerol stock, which was obtained after selection and identification of B. pseudomallei from a blood culture of an infected patient. The culture was used to set up a purity plate, and the resulting growth was used to make the glycerol stock. As the requested information is indeed relevant, we have now included these details in the Methods section (line 102). 2. How many independent isolates (colonies) of each strain were recovered? Response: We isolated four colonies of each morphotype (rough and smooth) from streaked plates prepared directly from the −80 °C stock. This information has been added to the Methods section (line 102). While we did not quantify the proportion of each morphotype, visual inspection of the streaked plates (Fig. 1A) suggests that TSV292_1 rough colonies are more prevalent than TSV292_2 smooth ones. 3. Based on 16S rRNA gene sequences, how distinct are the two strains? Response: Both isolates were initially identified using MLST sequencing, which offers higher resolution for distinguishing strains within the same species. In response to this comment, we also examined the 16S rRNA sequences and found that three of the four copies carried a G→A mutation at position 182 bp, indicating minor variation at the 16S level. Alignment of the MLST sequences revealed SNPs within several genes, resulting in the identification of distinct sequence types (STs). 4. From whole-genome sequencing, how extensive are the differences between the strains? Are there genes or long sequence regions unique to one strain, beyond mutations or mobile element–associated insertions/deletions consistent with divergence from a common ancestor? More specifically, what accounts for the larger genome size of TSV292_2 compared with TSV292_1, and does TSV292_1 retain any unique sequences despite its smaller genome? Response: Thank you for highlighting these questions. To address them, we have added the following analysis to the manuscript. We cross-compared the annotated gene sets from both assemblies by aligning each against the nucleotide sequences of the opposite isolate using BLASTn. Results with >90% sequence identity were retained and further cross-analyzed using the equivalent approach against the B. pseudomallei K96243 genome. Genes located within mobile element–associated insertion/deletion regions were subsequently excluded. This analysis identified only one unique gene in TSV292_R (TSV292_R_RS_00840), predicted to encode a hypothetical protein. According to the literature, this gene is downregulated when B. pseudomallei SZ5028 is grown in minimal medium with arabinose compared to glucose (DOI: 10.1128/IAI.72.7.4172–4187.2004). Furthermore, the difference in genome size between TSV292_1 and TSV292_2 is likely explained by the total size of the deleted/inserted genomic regions (94 kb in TSV292_1 and 357,022 bp in TSV292_2), as well as the number of duplicated genes (240,390 bp in TSV292_1 and 74 kb in TSV292_2). The methodology and corresponding results have now been detailed in the manuscript (lines 162, 352, and 376). 5. What is the likelihood that one strain (TSV292_1) is closely related to a previously isolated Townsville University Hospital strain? Could this reflect contamination from a preserved isolate rather than both strains representing true infection? Response: Thank you for your feedback regarding the potential for contamination. Isolate TSV292 was initially cultured, and a rough colony was sequenced, which resulted in a new sequence type (ST) described by Gasseip et al. (2024) [25]. The same study identified this ST within a cohort of approximately 200 TSV isolates. For the present study, all experimental steps—from streaking the isolate stock to genomic DNA extraction—were performed by a different researcher, and sequencing was conducted independently at another facility using both Illumina and Nanopore technologies. The resulting ST for TSV292_1 matched the previously described ST2323 [25], whereas TSV292_2 represented a novel ST, differing by over 22,000 mutations across the genome – alongside with deletions of multiple genomic regions between both isolates. Illumina reads were cross-mapped onto the assembled genome, and clear single-nucleotide polymorphisms (SNPs) were identified in MLST genes, each supported by at least 90% (often 100%) of the reads. These findings strongly suggest a genuine polyclonal infection rather than contamination. Nevertheless, we have added to the Discussion a consideration of alternative explanations that could account for the presence of two distinct isolates (from line 510). Without addressing these points, the conclusion of co-infection remains plausible but not definitive. Reviewer #2: Dear Editor, This manuscript reports the co-isolation of two genetically distinct Burkholderia pseudomallei strains (ST-2319 and ST-2323) from a single melioidosis patient in Townsville, Australia. Using an integrated multi-omics approach (Illumina and Nanopore genome sequencing, proteomics via ZenoTOF 7600 LC-MS/MS, and phenotypic assays), the authors demonstrate that what initially appeared as colony morphotype variation (CMV) actually represented a true polyclonal infection. The work highlights the diagnostic challenges posed by such cases and suggests that standard laboratory workflows may underestimate strain diversity in clinical B. pseudomallei isolates. This is a technically strong and novel contribution to melioidosis research. It fits PLOS ONE’s scope for methodological rigor and open data sharing. Here are some comments and suggestions: Methods clarity: - Specify sequencing coverage, read depth, and methylation-calling thresholds used for Nanopore data. Response: Thank you for noting the missing information regarding our sequencing data and methylation analysis parameters. Details on sequencing coverage and read depth have been provided in the “Genome assembly” method section (line 126), and the methylation-calling thresholds and related parameters are described in the “Methylome” method section (line 175). - Confirm whether proteomic and phenotypic assays were performed in biological triplicates or single replicates. Response: The number of replicates for phenotypic assays (4; line 253) and proteomic analyses (3) were originally included in the method. However, we have added a subsection to described how the samples were cultured for proteomic analyses (line 183) - Indicate if any of the reference strains (e.g., B. pseudomallei K96243) was included in phenotypic assays; if not, explain why. Response: Thank you for your comment. The reference isolate Bp K96243 was not included in our tests as, phenotypes are strain-specific. The same statement was added lines 260 and 276. Additional discussions: - Expand the discussion to address how polyclonality could influence antibiotic therapy outcomes, especially regarding the TMP-SMX resistance observed in the smooth isolate. Response: We have now included discussion relating to antibiotic resistance profile differing between both isolates and the potential consequences (line 533). - Discuss potential diagnostic challenges for PCR, MALDI-TOF, and serological assays when polyclonal infections occur. Response: Thank you for the suggestion, this has been added to the discussion from line 493. - Soften the statement “covert polyclonality rather than ultrafast evolution is a major driver…” to a more cautious phrasing (e.g., “may contribute significantly to observed genomic diversity”). Response: The statement has been changed as requested and can be found line 544. - Consider including additional references discussing the prevalence of polyclonal infections, such as, Kaewrakmuk et al PLoS Negl Trop Dis . 2024 Aug 22;18(8):e0012444, when multiple bacterial colonies were selected for genotypings. Response: Thank you for providing the reference. We have included it into the paper, in the abstract, introduction and discussion under ref [27] (lines 24; 82; 554). Submitted filename: Response to Editor and Reviewers.docx 20 Nov 2025 Co-isolation of genetically distinct Burkholderia pseudomallei strains from a single patient in North Queensland PONE-D-25-51165R1 Dear Dr. Coulon, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, William C. Nierman, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-51165R1 PLOS One Dear Dr. Coulon, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. William C. Nierman Academic Editor PLOS One